Next Investors logo grey

Creso Pharma’s flagship cannaQIX® exceeds milestone of 2.5 million lozenges sold


Published 28-JAN-2020 08:54 A.M.


2 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.

Click Here to View Latest Articles

Creso Pharma Limited (ASX:CPH, FRA:1X8) has informed the market that its flagship cannaQIX® line surpassed the milestone of 100,000 packs sold.

The company has already delivered positive news flow throughout January resulting in its share price increasing by more than 70% from about 11 cents at the start of the month to a high of 19 cents.

Importantly, this share price accretion is performance driven as Creso Pharma has achieved increased distribution in other areas of its business, as well as flagging its upcoming entry into new markets, factors that will assist the group in delivering on the anticipated strong revenue growth in 2020.

The cannaQIX® hemp oil derived food supplement is currently available in Switzerland, UK, Australia, Brazil and New Zealand.

Creso Pharma product line

2.5 million cannaQIX® lozenges sold

The 100,000 packs milestone corresponds to over 2.5 million cannaQIX® lozenges sold since the product’s launch in April 2018.

Creso Pharma developed cannaQIX® 10 to help manage stress and cannaQIX® 25 and 50 to help manage chronic pain.

The initial target markets for these products were the UK, Switzerland, Australia, New Zealand and Brazil.

Creso Pharma produces the cannaQIX® range of products in Switzerland and has commercialised them in collaboration with several partners in Europe, Oceania and Latin America.

The products are being distributed through pharmacies and drug stores in Europe, as well as through doctors and clinics in Oceania and Latin America.

Highlighting Creso Pharma’s expertise in the development of the cannaQIX® range and the decided benefits that the company’s technological capabilities will provide in strengthening its portfolio of products, Jorge Wernli, commercial director said, “Creso Pharma’s cannaQIX® hemp oil-derived products are unique, all Swiss-made and produced in GMP facilities complying with local regulatory requirements.

‘’Creso Pharma has developed a number of new alternative technologies to provide these innovative hemp oil-based products, responding to customer needs and complying with regulations.

‘’With our technological capabilities and international scientific and commercial partnerships, we are well-positioned to continue growing our portfolio of commercialised animal and human health products.”

General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.